Post-Campylobacter Guillain Barre Syndrome in the USA: secondary analysis of surveillance data collected during the 2009-2010 novel Influenza A (H1N1) vaccination campaign

被引:17
作者
Halpin, A. Laufer [1 ,2 ]
Gu, W. [1 ]
Wise, M. E. [3 ]
Sejvar, J. J. [4 ]
Hoekstra, R. M. [1 ]
Mahon, B. E. [1 ]
机构
[1] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA
[2] CDC, Epidem Intelligence Serv, Sci Educ & Profess Dev Program, Atlanta, GA 30333 USA
[3] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA
[4] CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA
关键词
Campylobacter; Guillain-Barre syndrome; incidence; surveillance; INTENSIVE-CARE-UNIT; INFECTION; JEJUNI; VACCINES; STATES; MORBIDITY; PATHOGENS; FEATURES; PROGRAM; SITES;
D O I
10.1017/S0950268818001802
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Guillain Barre syndrome (GBS), which is triggered by autoantibodies produced in response to antigenic stimuli such as certain infections and vaccinations, is the most common cause of acute flaccid paralysis worldwide. Campylobacter, the most common bacterial enteric infection in the USA, is reported to be the most commonly diagnosed antecedent of GBS, yet little information is available about the risk of post-Campylobacter GBS. Data collected through active, population-based surveillance in the Emerging Infections Program during the 2009-2010 novel Influenza A (H1N1) vaccination campaign allowed us to compare confirmed and probable GBS cases to non-cases to determine whether antecedent Campylobacter infection (or a diarrhoeal illness consistent with campylobacteriosis) was more common among cases and to assess the risk of GBS following Campylobacter infection. We estimate that 812% of GBS cases in the USA are attributable to Campylobacter infection (or a diarrhoea) illness consistent with campylobacteriosis), with 434-650 cases of post-diarrhocal GBS annually and about 49 cases of GBS per 100 000 Campylobacter infections. These results provide updated estimates for post-Campylobacter GBS incidence in the USA and highlight an important benefit of effective measures to prevent Campylobacter infections.
引用
收藏
页码:1740 / 1745
页数:6
相关论文
共 39 条
[1]  
[Anonymous], 2015, CURRENT POLITICS EC
[2]   Epidemiologic and clinical features of Campylobacter jejuni infections [J].
Blaser, MJ .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 :S103-S105
[3]  
Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P41
[4]  
Crim SM, 2014, MMWR-MORBID MORTAL W, V63, P328
[5]   Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team [J].
Dawood, Fatimah S. ;
Jain, Seema ;
Finelli, Lyn ;
Shaw, Michael W. ;
Lindstrom, Stephen ;
Garten, Rebecca J. ;
Gubareva, Larisa V. ;
Xu, Xiyan ;
Bridges, Carolyn B. ;
Uyeki, Timothy M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (25) :2605-2615
[6]   The morbidity and outcome of patients With Guillain-Barre syndrome admitted to the intensive care unit [J].
Dhar, Rajat ;
Stitt, Larry ;
Hahn, Angelika F. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 264 (1-2) :121-128
[7]   ROLE OF INFECTION IN GUILLAIN-BARRE-SYNDROME - LABORATORY CONFIRMATION OF HERPESVIRUSES IN 41 CASES [J].
DOWLING, PC ;
COOK, SD .
ANNALS OF NEUROLOGY, 1981, 9 :44-55
[8]  
Eltayeb KG, 2012, BMJ CASE REPORTS, V2012, P1, DOI [10.1136/bcr.02.2012.5868, DOI 10.1136/BCR.02.2012.5868]
[9]   Economic cost of Guillain-Barre syndrome in the United States [J].
Frenzen, P. D. .
NEUROLOGY, 2008, 71 (01) :21-27
[10]   Vaccines and Guillain-Barre Syndrome [J].
Haber, Penina ;
Sejvar, James ;
Mikaeloff, Yann ;
DeStefan, Frank .
DRUG SAFETY, 2009, 32 (04) :309-323